Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Stock Has Average Price Target of $99.07

Key Points

• Analysts are moderately bullish on Arrowhead Pharmaceuticals, with 10 buy ratings, one strong buy, three holds and one sell among 15 analysts. The average 12-month price target is $99.07, with recent targets ranging from $95 to $123.
• Arrowhead reported quarterly revenue of $75.25 million, up 171% year over year and above estimates, but its loss of $1.36 per share exceeded the expected $1.23 loss. Analysts expect a full-year loss of approximately $3.62 per share.
• The stock opened at $58.36, well below its 52-week high of $95.49, while two directors recently sold a combined 13,600 shares. Institutional investors own 62.61% of the company.

Shares of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR - Get Free Report) have earned a consensus recommendation of "Moderate Buy" from the fifteen brokerages that are covering the firm, Marketbeat.com reports. One investment analyst has rated the stock with a sell recommendation, three have assigned a hold recommendation, ten have issued a buy recommendation and one has issued a strong buy recommendation on the company. The average 1-year price objective among brokerages that have updated their coverage on the stock in the last year is $99.07.

A number of research firms have recently commented on ARWR. UBS Group assumed coverage on Arrowhead Pharmaceuticals in a research report on Thursday, October 15th. They issued a "buy" rating and a $109.00 price objective for the company. HC Wainwright reiterated a "buy" rating and set a $120.00 target price on shares of Arrowhead Pharmaceuticals in a research report on Thursday, October 15th. Weiss Ratings reiterated a "sell (d-)" rating on shares of Arrowhead Pharmaceuticals in a research report on Monday, August 17th. JPMorgan Chase & Co. lifted their price target on shares of Arrowhead Pharmaceuticals from $88.00 to $95.00 and gave the company an "overweight" rating in a research note on Friday, July 17th. Finally, B. Riley Financial boosted their price target on shares of Arrowhead Pharmaceuticals from $101.00 to $123.00 and gave the stock a "buy" rating in a report on Thursday, July 30th.

Arrowhead Pharmaceuticals Price Performance

NASDAQ:ARWR opened at $58.36 on Friday. The company has a quick ratio of 5.90, a current ratio of 5.90 and a debt-to-equity ratio of 1.77. Arrowhead Pharmaceuticals has a 52 week low of $36.73 and a 52 week high of $95.49. The stock's 50-day moving average price is $73.19 and its 200-day moving average price is $75.88. The stock has a market capitalization of $8.22 billion, a PE ratio of -25.94 and a beta of 1.29.

Arrowhead Pharmaceuticals (NASDAQ:ARWR - Get Free Report) last released its quarterly earnings results on Tuesday, August 4th. The biotechnology company reported ($1.36) earnings per share for the quarter, missing analysts' consensus estimates of ($1.23) by ($0.13). The business had revenue of $75.25 million during the quarter, compared to analyst estimates of $44.17 million. Arrowhead Pharmaceuticals had a negative return on equity of 60.06% and a negative net margin of 47.79%. The business's revenue for the quarter was up 171.0% compared to the same quarter last year. During the same period in the previous year, the company posted ($1.26) EPS. As a group, equities analysts expect that Arrowhead Pharmaceuticals will post -3.62 EPS for the current fiscal year.

Insider Buying and Selling at Arrowhead Pharmaceuticals

In other Arrowhead Pharmaceuticals news, Director Adeoye Olukotun sold 2,000 shares of the stock in a transaction on Tuesday, August 18th. The shares were sold at an average price of $86.96, for a total transaction of $173,920.00. Following the transaction, the director directly owned 31,600 shares of the company's stock, valued at $2,747,936. This trade represents a 5.95% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, Director Michael Perry sold 11,600 shares of Arrowhead Pharmaceuticals stock in a transaction dated Tuesday, August 18th. The shares were sold at an average price of $87.30, for a total transaction of $1,012,680.00. Following the completion of the sale, the director owned 111,459 shares in the company, valued at approximately $9,730,370.70. This trade represents a 9.43% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Company insiders own 3.60% of the company's stock.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Optiver Holding B.V. increased its stake in Arrowhead Pharmaceuticals by 83.8% during the 1st quarter. Optiver Holding B.V. now owns 408 shares of the biotechnology company's stock worth $26,000 after buying an additional 186 shares in the last quarter. Versant Capital Management Inc raised its holdings in shares of Arrowhead Pharmaceuticals by 285.1% during the second quarter. Versant Capital Management Inc now owns 335 shares of the biotechnology company's stock valued at $27,000 after acquiring an additional 248 shares during the last quarter. Carolina Wealth Advisors LLC raised its holdings in shares of Arrowhead Pharmaceuticals by 80.6% during the second quarter. Carolina Wealth Advisors LLC now owns 345 shares of the biotechnology company's stock valued at $28,000 after acquiring an additional 154 shares during the last quarter. Persistent Asset Partners Ltd acquired a new position in shares of Arrowhead Pharmaceuticals during the second quarter valued at approximately $39,000. Finally, First Horizon Corp lifted its position in shares of Arrowhead Pharmaceuticals by 36.2% in the first quarter. First Horizon Corp now owns 654 shares of the biotechnology company's stock valued at $41,000 after acquiring an additional 174 shares in the last quarter. 62.61% of the stock is owned by hedge funds and other institutional investors.

Arrowhead Pharmaceuticals Company Profile

Arrowhead Pharmaceuticals, Inc is a biopharmaceutical company focused on developing medicines that silence disease-causing genes using RNA interference (RNAi). The company's proprietary Targeted RNAi Molecule (TRiM) platform is designed to deliver RNAi-based therapies to specific tissues and reduce the production of targeted proteins.

Arrowhead's research and development programs address a range of conditions, including cardiometabolic, pulmonary, liver, and central nervous system diseases.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.